IGC Pharma Reports Third Quarter Fiscal 2025 Results

Rhea-AI Summary

IGC Pharma reported its Q3 FY2025 financial results, highlighting progress in its Phase 2 CALMA trial for IGC-AD1, aimed at reducing agitation in Alzheimer's patients. The company generated $257,000 in revenue, a 26% increase from the same period last year, driven by white-label sales of over-the-counter formulations.

Key financial metrics show SG&A expenses decreased by 49% to $1.0 million, while R&D expenses decreased by 6% to $852,000. The net loss was $1.8 million ($0.02 per share), compared to $5.8 million ($0.08 per share) in the previous year. The company plans to expand IGC-AD1's application as an Alzheimer's disease-modifying therapy targeting brain plaques and tangles.

Notable achievements include winning two PREPARE Challenge awards and enrolling patients at Baycrest Academy in Toronto for the CALMA trial. The company also reported positive interim data showing cognitive benefits in Alzheimer's patients.

Positive

• Revenue increased 26% year-over-year to $257,000
• SG&A expenses decreased significantly by 49% to $1.0 million
• Net loss per share improved from $0.08 to $0.02
• Positive interim data reported from CALMA trial showing cognitive benefits
• $12 million credit line remains available and unused

Negative

• Company still operating at a net loss of $1.8 million
• Revenue remains relatively low at $257,000 quarterly

Insights

Financial Analyst

IGC Pharma's Q3 FY2025 results reveal a company effectively balancing fiscal discipline with strategic expansion in the Alzheimer's therapeutic space. The 26% revenue growth to $257,000, while modest in absolute terms, demonstrates traction in their white-label OTC business strategy. More significantly, the 69% reduction in net loss to $1.8 million showcases successful cost management initiatives, particularly through the 49% reduction in SG&A expenses.

The company's strategic pivot toward Alzheimer's disease-modifying therapy represents a important expansion of their addressable market. The current global Alzheimer's therapeutics market, valued at approximately $4 billion, is projected to grow substantially with the emergence of disease-modifying treatments. IGC-AD1's dual positioning - both for agitation management and as a potential disease-modifying therapy - could significantly enhance its commercial viability.

The NIH PREPARE Challenge recognition strengthens IGC's credibility in AI-driven Alzheimer's research, potentially facilitating future research partnerships and funding opportunities. The positive interim data from the CALMA trial, particularly regarding cognitive benefits, adds another layer of validation to their clinical program.

From a financial sustainability perspective, the untapped $12 million credit facility provides important operational runway as the company advances its clinical programs. The 6% decrease in R&D expenses to $852,000 reflects efficient resource allocation rather than reduced research commitment, as evidenced by the ongoing CALMA trial progress and expansion into disease-modifying therapy research.

POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024.

IGC Pharma, Inc.
IGC Pharma, Inc.

"The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr. Ram Mukunda, CEO. "We are also planning to explore IGC-AD1 as an Alzheimer's disease-modifying therapy, aimed at reducing plaques and tangles in the brain, which positions IGC-AD1 in a significantly broader market. Our AI-driven research also gained recognition from the NIH through the PREPARE Challenge, reinforcing our leadership in Alzheimer's innovation. As we continue executing our strategy across Alzheimer's and metabolic disorders, we remain committed to delivering transformative therapies and driving long-term value for shareholders."

Q3 FY2025 Company's Highlights:

• Recognition in Innovative Research: On October 1, 2024, IGC Pharma celebrated winning two awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer's and Related Dementias EUREKA Challenge), for its compelling entry based on the Mexican Health and Aging Study ("MHAS") database.

• Patient Enrollment in Toronto: The Company marked a significant milestone on October 17, 2024, with the enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, as part of its ongoing CALMA trial focusing on the treatment of agitation in Alzheimer's dementia.

• Positive Interim Data Revealed: On November 14, 2024, IGC Pharma announced additional interim data from its ongoing CALMA trial highlighting cognitive benefits of IGC-AD1 in Alzheimer's patients.

• Expansion into Alzheimer's Disease Modifying Treatment: On December 2, 2024, IGC Pharma announced an expansion of its clinical research program for IGC-AD1, to address cognitive impairment and underlying Alzheimer's disease pathology, such as reduction of plaques and tangles.

Financial Summary

During the three months ended December 31, 2024, the Company generated approximately $257 thousand in revenue representing an increase of 26% compared to the approximately $204 thousand generated during the three months ended December 31, 2023. The increase in revenue is attributed to white-label sales of our over-the-counter formulations. The Company is committed to its current strategy of driving sales in formulations both as branded and white-labeled products.

During the three months ended December 31, 2024, the Company reported Selling, general and administrative expenses ("SG&A") expenses decreased by approximately $1.1 million or 49% to approximately $1.0 million, from approximately $2.2 million recorded for the three months ended December 31, 2023. The decrease of $1.1 million is attributed to a one-time expense of approximately $734 thousand during the three months ended December 31, 2023, and the focus of management on cost efficiency in marketing and corporate expenses during the three months ended December 31, 2024.

During the three months ended December 31, 2024, the Company reported Research and Development ("R&D") expenses of approximately $852 thousand, representing a decrease of approximately $51 thousand or 6% compared to the three months ended December 31, 2023. It is primarily attributable to the progression of CALMA Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets.

The net loss for the three months ended December 31, 2024, was approximately $1.8 million or $0.02 per share, compared to approximately $5.8 million or $0.08 per share for three months ended December 31, 2023.

As of December 31, 2024, the Company has not drawn on the $12 million available under the Credit Agreement with O-Bank.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

Contact Information

Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

< Financial Tables to Follow>

CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
(Unaudited)

		December 31, 2024 ($)				March 31, 2024 ($)
ASSETS
Current assets:
Cash and cash equivalents			470				1,198
Accounts receivable, net			49				39
Inventory			1,433				1,540
Asset held for sale			701				720
Deposits and advances			398				208
Total current assets			3,051				3,705
Non-current assets:
Intangible assets, net			1,869				1,616
Property, plant, and equipment, net			3,348				3,695
Claims and advances			681				688
Operating lease asset			129				198
Total non-current assets			6,027				6,197
Total assets			9,078				9,902
LIABILITIES AND STOCKHOLDERS EQUITY
Current liabilities:
Accounts payable			835				773
Accrued liabilities and others			1,822				1,567
Total current liabilities			2,657				2,340
Non-current liabilities:
Long-term loans			134				137
Other liabilities			16				20
Operating lease liability			12				84
Total non-current liabilities			162				241
Total liabilities			2,819				2,581
Commitments and Contingencies - See Note 12
Stockholders equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of December 31, 2024, and March 31, 2024.
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 78,203,218 and 66,691,195 shares issued and outstanding as of December 31, 2024, and March 31, 2024, respectively.			129,307				124,409
Accumulated other comprehensive loss			(3,459	)			(3,423	)
Accumulated deficit			(119,589	)			(113,665	)
Total stockholders equity			6,259				7,321
Total liabilities and stockholders equity			9,078				9,902

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended December 31, 2024, filed with the SEC on February 14, 2025.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except loss per share and share data)
(Unaudited)

		Three months ended December 31,								Nine months ended December 31,
		2024				2023				2024				2023
		($)				($)				($)				($)
Revenue			257				204				941				1,050
Cost of revenue			(153	)			(71	)			(476	)			(488	)
Grossprofit			104				133				465				562
Selling, general and administrative expenses			(1,130	)			(2,228	)			(3,841	)			(5,272	)
Research and development expenses			(852	)			(903	)			(2,658	)			(2,918	)
Operating loss			(1,878	)			(2,998	)			(6,034	)			(7,628	)
Impairment Loss on PPE			-				(2,623	)			-				(2,623	)
Other income, net			49				32				110				136
Loss before income taxes			(1,829	)			(5,589	)			(5,924	)			(10,115	)
Income tax expense/benefit			-				-				-				-
Net loss attributable to common stockholders			(1,829	)			(5,589	)			(5,924	)			(10,115	)
Foreign currency translation adjustments			(18	)			18				(36	)			(36	)
Comprehensive loss			(1,847	)			(5,571	)			(5,960	)			(10,151	)
Net loss per share attributable to common stockholders:
Basic and diluted		$	(0.02	)			(0.09	)			(0.08	)			(0.18	)
Weighted-average number of shares used in computing net loss per share amounts:			77,633,004				63,725,084				75,494,270				57,039,035

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended December 31, 2024, and was filled with the SEC on February 14, 2025.

Contact Information

Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What was IGC's revenue growth in Q3 FY2025?

IGC reported a 26% revenue increase to $257,000 in Q3 FY2025 compared to $204,000 in the same period last year.

How much did IGC reduce its net loss per share in Q3 FY2025?

IGC reduced its net loss per share from $0.08 in Q3 FY2024 to $0.02 in Q3 FY2025.

What progress did IGC make in its CALMA trial during Q3 FY2025?

IGC enrolled patients at Baycrest Academy in Toronto and reported positive interim data showing cognitive benefits of IGC-AD1 in Alzheimer's patients.

How much did IGC's SG&A expenses decrease in Q3 FY2025?

IGC's SG&A expenses decreased by 49% or $1.1 million to $1.0 million compared to the same period last year.

What new therapeutic direction is IGC exploring for IGC-AD1?

IGC is expanding IGC-AD1's application as an Alzheimer's disease-modifying therapy aimed at reducing plaques and tangles in the brain.